Taken together, our findings demonstrated that LINC00673 silencing could disrupt the methylation of the KLF4 gene promoter and consequently suppress cell proliferation and drug resistance in prostate cancer (Figure 8), illuminating potential for future therapeutic strategies for prostate cancer. Here, LINC00511 is linked to prostate cancer.